NCT02604160View on ClinicalTrials.gov

A Study of LY3113593 in Participants With Chronic Kidney Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

November 17, 2015

Primary Completion Date

June 22, 2016

Study Completion Date

June 22, 2016

Conditions
Chronic Kidney Disease
Interventions
DRUG

LY3113593

Administered by slow intravenous (IV) infusion.

DRUG

Placebo

Administered by slow intravenous (IV) infusion.

Trial Locations (5)

32806

Orlando Clinical Research Center, Orlando

46202

Indiana University School of Medicine, Indianapolis

55404

DaVita Clinical Research, Minneapolis

71101

Northwest Louisiana Nephrology, Shreveport

78215

Clinical Advancement Center, PLLC, San Antonio

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT02604160 - A Study of LY3113593 in Participants With Chronic Kidney Disease | Biotech Hunter | Biotech Hunter